

Tumor Biomarkers

References

1. American Cancer Society. Cancer facts and figures 1996 American Cancer Society Atlanta.
2. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, *et al.* Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. *Science Translational Medicine*. 2011;3(75):12.
3. Sturgeon CM, Duffy MJ, Stenman UH, *et al.* National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers, *Clin Chem*, 2008, vol. 54 (pg. e11-e79)
4. McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care, *N Engl J Med*, 2011, vol. 364 (pg. 340-350)
5. Li D, Mallory T, Satomura S. AFP-L3: A new generation of tumor marker for hepatocellular carcinoma. *Clin Chim Acta*. 2001;313:15–19. doi: 10.1016/S0009-8981(01)00644-1.
6. Leerapun, Apinya *et al.* "The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population" *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* vol. 5,3 (2007): 394-402; quiz 267.
7. Felder, Mildred *et al.* "MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress" *Molecular cancer* vol. 13 129. 29 May. 2014, doi:10.1186/1476-4598-13-129
8. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. *Clinica chimica acta; international journal of clinical chemistry*. 2010;411:1869–74.
9. Ballehaninna, Umashankar K and Ronald S Chamberlain. "Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review" *Indian journal of surgical oncology* vol. 2,2 (2011): 88-100.
10. Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Casaldi V, Wappner G, Abbolito MR, Greiner JW, *et al.* CA 72-4 serum marker—a new tool in the management of carcinoma patients. *Cancer Invest*. 1995;13(2):227–238. doi: 10.3109/07357909509011692
11. Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. *Microsc Res Tech*. 2002;59:102–8. doi: 10.1002/jemt.10181
12. Li, Jinping *et al.* "HE4 as a biomarker for ovarian and endometrial cancer management" *Expert review of molecular diagnostics* vol. 9,6 (2009): 555-66.
13. Konev AA, Smolyanova TI, Kharitonov AV, Serebryanaya DV, Kozlovsky SV, Kara AN, Feygina EE, Katrukha AG, Postnikov AB. Characterization of endogenously circulating IGFBP-4 fragments—novel biomarkers for cardiac risk assessment. *Clin Biochem*. 2015;48:774–780.
14. Mosig, Rebecca A *et al.* "IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer" *Journal of ovarian research* vol. 5,1 3. 20 Jan. 2012, doi:10.1186/1757-2215-5-3
15. Wu, Tianfu *et al.* "Insulin-Like Growth Factor Binding Protein-4 as a Marker of Chronic Lupus Nephritis" *PloS one* vol. 11,3 e0151491. 28 Mar. 2016, doi:10.1371/journal.pone.0151491
16. Nath, Sritama and Pinku Mukherjee. "MUC1: a multifaceted oncoprotein with a key role in cancer progression" *Trends in molecular medicine* vol. 20,6 (2014): 332-42.
17. Tinder, Teresa L *et al.* "MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma" *Journal of immunology (Baltimore, Md. : 1950)* vol. 181,5 (2008): 3116-25.
18. Isgro M. A., Bottoni P., Scatena R. Neuron-specific enolase as a biomarker: biochemical and clinical aspects. *Advances in Experimental Medicine and Biology*. 2015;867:125–143. doi: 10.1007/978-94-017-7215-0_9.
19. Prensner, John R *et al.* "Beyond PSA: the next generation of prostate cancer biomarkers" *Science translational medicine* vol. 4,127 (2012): 127rv3.